• linkedin
  • Increase Font
  • Sharebar

    Data support adding suprachoroidal injection to anti-VEGF for RVO

    Additive approach augments results of intravitreal anti-VEGF with encouraging safety profile

     

     

    Safety review

    The safety review showed no cases of cataract exacerbation in the combination therapy group. Two eyes (8.7%) developed IOP ≥30 mm Hg, and both were controlled on topical medication.

    “Because this was a small study with short follow-up, we would not expect to see any significant corticosteroid-induced cataract changes,” Dr. Brown said. “The safety of suprachoroidal triamcinolone acetonide will receive further scrutiny in trials of its use in uveitis that are investigating multiple doses and over longer follow-up.” 

     

    David M. Brown, MD

    E: [email protected]

    This article was adapted from Dr. Brown’s presentation at Retina Subspecialty Day during the 2016 meeting of the American Academy of Ophthalmology. Dr. Brown receives research grant funding and is a consultant/scientific advisory board member for Clearside Biomedical and other companies marketing or developing treatments for retinal vein occlusion.

     

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';